This commentary on a case considers a transgender patient’s mental health and risk for DVT in ethical decision making about feminizing gender-affirming hormone therapy.
AMA J Ethics. 2023;25(6):E386-390. doi:
10.1001/amajethics.2023.386.
Lee C. Zhao, MD, Gaines Blasdel, Augustus Parker, and Rachel Bluebond-Langner, MD
Tension between realistic goals and unrealistic views about how to achieve them is compounded when patients are eager to revise a prior surgeon’s gender-affirming procedure.
AMA J Ethics. 2023;25(6):E391-397. doi:
10.1001/amajethics.2023.391.
Before the late 20th century, overweight and obesity were not considered population-wide health risks, but the advent of weight loss drugs in the 1990s accelerated hypermedicalization via BMI use.
AMA J Ethics. 2023;25(7):E550-558. doi:
10.1001/amajethics.2023.550.